Regeneron (REGN +9.4%) pops on a blowout Q1, posting a surprise profit on a revenue number that...

|About: Regeneron Pharmaceuticals, ... (REGN)|By:, SA News Editor

Regeneron (REGN +9.4%) pops on a blowout Q1, posting a surprise profit on a revenue number that was easily 30% above consensus estimates. Total revenue doubled on record sales of Eyelea that came in at nearly twice consensus estimates. The company adds that the outperformance is likely to continue, and doubles its 2012 revenue expectations for the drug. Baird says the results were “bigger than our wildest expectations.”